AbbVie Inc.

Jim Cramer on Johnson & Johnson: “It’s a Textbook Slowdown Stock”

Johnson & Johnson (NYSE:JNJ) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. Cramer was quite bullish on the company’s stock, as he stated: Yesterday, we got some terrific news from Johnson & Johnson, but because the tape was so ugly, the stock did

Source: Insider Monkey Mar 21, 2026

The Market’s Favorite Active ETF Was Made for This Moment. Is It Delivering?

JPMorgan Equity Premium Income ETF (JEPI) is built to cushion volatility, but investors may find stronger returns in defensive sectors and dividend funds.

Source: Barrons.com Mar 20, 2026

Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why

PTGX stock jumps as JNJ wins FDA nod for Icotyde in plaque psoriasis, unlocking milestone payments and royalty potential for Protagonist.

Source: Zacks Mar 20, 2026

Is AbbVie (ABBV) Quietly Rewiring Its Immunology Edge With Alloy’s Antibody Discovery Deal?

On 17 March 2026, Alloy Therapeutics announced a multi-year agreement giving AbbVie access to its ATX-Gx-based antibody discovery platform, with Alloy receiving an upfront payment and additional compensation upon delivering the platform. This collaboration adds another specialized discovery engine to AbbVie’s research toolkit, potentially broadening its ability to address complex biological targets beyond its current technologies. We’ll now examine how AbbVie’s access to Alloy’s...

Source: Simply Wall St. Mar 20, 2026

The Only 3 Growth ETFs I Would Buy and Hold Through Any Market

Growth investing has had a choppy start to 2026. The major growth benchmarks are down in the low single digits year-to-date, and some of the biggest names in tech have pulled back meaningfully from their late-2025 highs. For investors with a multi-year horizon, that kind of consolidation is worth understanding in the context of each ... The Only 3 Growth ETFs I Would Buy and Hold Through Any Market

Source: 24/7 Wall St. Mar 20, 2026

JP Morgan’s Dividend Leaders ETF Sounds Good, But The Yield Underwhelms

JPMorgan Dividend Leaders ETF (NYSEARCA:JDIV) launched in September 2024 with an appealing premise: a curated portfolio of global dividend leaders. The name implies income. The reality is a 1.59% yield at a time when the 10-year Treasury sits at 4.20%. That gap is hard to ignore for income-focused investors. Metric Value Dividend Yield 1.59% Net ... JP Morgan’s Dividend Leaders ETF Sounds Good, But The Yield Underwhelms

Source: 24/7 Wall St. Mar 20, 2026